Resyca

Executive Summary

Resyca is a Netherlands-based drug delivery company specializing in proprietary soft mist inhalation and nasal spray technologies. Founded in 2012 and headquartered in Wageningen, the company develops and licenses innovative devices designed to deliver high-dose biologics, mRNA, and other complex formulations without degradation. Its platform addresses key challenges in pulmonary and nasal drug delivery, enabling improved therapeutic precision and patient experience for a range of indications. As a joint venture, Resyca focuses on drug-device combination products that can enhance the efficacy and stability of sensitive therapies. The company's technology is particularly relevant for vaccines, respiratory diseases, and systemic conditions requiring non-invasive administration. While Resyca remains a private entity with limited public financial disclosures, its position in the growing inhalation and nasal drug delivery market—projected to reach $60+ billion by 2030—offers significant potential. The company's partnerships with biopharmaceutical firms to co-develop or license its devices serve as key value drivers. With increasing demand for advanced delivery systems for biologics and mRNA, Resyca's ability to provide high-dose capacity and formulation integrity positions it as a strategic enabler in the biotech ecosystem. Future growth hinges on securing commercial partnerships and regulatory approvals for its platform across multiple therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a Major Biopharma for mRNA Inhalation Delivery40% success
• Q4 2026FDA Clearance of Nasal Spray Device for Biologics35% success
• Q2 2026Licensing Deal for Pulmonary Delivery of a Late-Stage Biologic50% success